Posted by Michael Wonder on 25 Apr 2024
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young people with an aggressive form of brain cancer, has today been recommended by NICE.
Dabrafenib (also known as Finlee) in combination with trametinib (also known as Spexotras, both made by Novartis) is being recommended in final draft guidance for treating BRAF V600E mutation positive glioma.
